ALB and focal segmental glomerulosclerosis: To determine if vincristine directly alters glomerular permeability, we used a GOAC31 model and performed FITC-albumin flow-through experiments following addition of either FBS (Figure 4a), 5 ng/ml vincristine (the lowest dose used in our earlier experiments, Figure 4b), 1% presentation serum from the index patient 1 with FSGS without (Figure 4c) or with 5 ng/ml vincristine (Figure 4d) for 24 hours (n = 4 repeats/condition).